The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 701–800 of 1,000
Corti, C., & Criscitiello, C. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100063 · Cited by 18
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist
Canino, F., Omarini, C., Cerma, K., Moscetti, L. I., Tornincasa, A., Trudu, L., Dominici, M., & Piacentini, F. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.02.002 · Cited by 17
Gastric Cancer and the Immune System: The Key to Improving Outcomes?
Keshavjee, S., Moy, R. H., Reiner, S. L., Ryeom, S. W., & Yoon, S. S. (2022) · Cancers · doi:10.3390/cancers14235940 · Cited by 17
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
Essâdi, I., Benbrahim, Z., Kaakoua, M., Reverdy, T., Corbaux, P., & Freyer, G. (2023) · Cancers · doi:10.3390/cancers15061738 · Cited by 18
Kong, C., Pu, J., Zhao, Q., Weng, W., Ma, L., Qian, Y., Hu, W., Meng, X., & Meng, T. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0164 · Cited by 17
Bhardwaj, P. V., & Abdou, Y. G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad233 · Cited by 18
Monteiro, M. R., Nunes, N., Junior, A., Fêde, Â., Bretas, G. D. O., Souza, C. D. P., Mano, M. S., & da Silva, J. L. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s448191 · Cited by 18
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
Afzal, M. Z., & Vahdat, L. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070719 · Cited by 17
Neuroendocrine neoplasms of the breast: a review of literature
Vegni, F., Stefano, I. S. D., Policardo, F., Tralongo, P., Feraco, A., Carlino, A., Ferraro, G., Zhang, Q., Scaglione, G., D’Alessandris, N., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03856-y · Cited by 17
FLI-1-driven regulation of endothelial cells in human diseases
Zhang, L., Ge, T., & Cui, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05546-4 · Cited by 17
Self-citationSynergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy
Pinto, A., Guarini, C., Giampaglia, M., Sanna, V., Melaccio, A., Lanotte, L., Santoro, A. N., Pini, F., Cusmai, A., Giuliani, F., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091146 · Cited by 17
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 18
Chan, W., Lam, T., Lam, K. O., Luk, M., Kai-Cheong, R. N., & Kwong, L. W. D. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920953729 · Cited by 18
Chowdari, N. S., Zhang, Y., McDonald, I. M., Johnson, W. L., Langley, D. R., Sivaprakasam, P., Mate, R. A., Huynh, T., Kotapati, S., Deshpande, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01385 · Cited by 17
Crespo, J., Sun, H., Wu, J., Ding, Q.-Q., Tang, G., Robinson, M. K., Chen, H., Şahin, A. A., & Lim, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241775 · Cited by 18
Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
Hamilton, J. Z., Pires, T. A., Mitchell, J. A., Cochran, J. H., Emmerton, K. K., Zaval, M. C., Stone, I. J., Anderson, M. E., Jin, S., Waight, A. B., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000889 · Cited by 17
China's Hainan Free Trade Port: Medical Laws and Policy Reform
Qi, F., Wu, Y., Wang, J., & Wang, Q. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.764977 · Cited by 17
Yin, S., Chi, Y., Du, Y., Wang, J., Shan, C., Yi, W., Shang, M., Man, X., Tan, Q., & Li, H. (2022) · Cancer Medicine · doi:10.1002/cam4.5056 · Cited by 17
Siddiqui, T., Rani, P., Ashraf, T., & Ellahi, A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104665 · Cited by 17
Antibody-drug conjugates combinations in cancer treatment
Pretelli, G., Mati, K., Motta, L., & Stathis, A. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00243 · Cited by 17
Gorzeń, O., Łęcka, M., Ćwilichowska-Puślecka, N., Majchrzak, M., Horbach, N., Wiśniewski, J. Ł., Jakimowicz, P., Szpot, P., Zawadzki, M., Dołęga-Kozierowski, B., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114269 · Cited by 16
Lüftner, D., Schneeweiß, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1111-8775 · Cited by 18
Lee, H. J., Shin, S., Kang, J.-H., Han, K.-C., Kim, Y. H., Bae, J., & Park, K. H. (2020) · Cancers · doi:10.3390/cancers12092630 · Cited by 16
Biosimilars in an Era of Rising Oncology Treatment Options
Peeters, M., Planchard, D., Pegram, M. D., Gonçalves, J., Bocquet, F., & Jang, H. (2021) · Future Oncology · doi:10.2217/fon-2021-0546 · Cited by 16
Saito, A., Yoshida, H., Nishikawa, T., & Yonemori, K. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.868 · Cited by 17
Chung, C., Yeung, V. T. Y., & Wong, K. C. W. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221119797 · Cited by 17
Iihara, H., Shimokawa, M., Bando, H., Niwa, Y., Mizuno, Y., Kawaguchi, Y., Kitahora, M., Murakami, A., Kawai, M., Ishida, K., et al. (2023) · Journal of Cancer · doi:10.7150/jca.87169 · Cited by 18
Steenbruggen, T. G., Wolf, D. M., Campbell, M. J., Sanders, J., Cornelissen, S., Thijssen, B., Salgado, R., Yau, C. S. F., O’Grady, N., Basu, A. B., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01717-1 · Cited by 17
Cardiotoxicity of Agents Used in Patients With Breast Cancer
Zagami, P., Trapani, D., Nicolò, E., Corti, C., Valenza, C., Criscitiello, C., Curigliano, G., & Carey, L. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00494 · Cited by 18
Tang, L., Sun, C., Liu, W., Wu, H., & Ding, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362484 · Cited by 16
Morgovan, C., Dobrea, C. M., Butucă, A., Arseniu, A. M., Frum, A., Rus, L. L., Chiş, A. A., Juncan, A. M., Gligor, F. G., Georgescu, C., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050953 · Cited by 16
Petit, T., Hajjaji, N., Antoine, É.-C., Benderra, M., Gozy, M., Foa, C., Mouysset, J., Grenier, J., Mousseau, M., Mailliez, A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7168 · Cited by 16
Crimini, E., & Curigliano, G. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2376573 · Cited by 17
Taha, Z., Crupi, M. J. F., Alluqmani, N., MacKenzie, D., Vallati, S., Whelan, J. T., Fareez, F., Alwithenani, A., Petryk, J., Chen, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51498-0 · Cited by 16
Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions
Pacholczak‐Madej, R., Meluch, M., & Püsküllüoğlu, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189369 · Cited by 16
Biomarkers in Her2- Positive Disease
Klocker, E. V., & Suppan, C. (2020) · Breast Care · doi:10.1159/000512283 · Cited by 16
Kubota, S., Hara, H., & Hiroi, Y. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01024 · Cited by 16
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
Duranti, S., Fabi, A., Filetti, M., Falcone, R., Lombardi, P., Daniele, G., Franceschini, G., Carbognin, L., Palazzo, A., Garganese, G., et al. (2021) · Cancers · doi:10.3390/cancers13205198 · Cited by 16
Advances in the management of breast cancer brain metastases
Sammons, S. L., Swearingen, A. E. D. V., Chung, C. D., & Anders, C. K. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab119 · Cited by 16
Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
Ferrario, C., Christofides, A., Joy, A. A., Laing, K. E., Gelmon, K. A., & Brezden‐Masley, C. (2022) · Current Oncology · doi:10.3390/curroncol29040222 · Cited by 16
Wu, F., Gardinier, T. C., Turker, M. Z., Chen, F., Chen, P.-M., Venkatesan, A. M., Patel, V., Adams, G. P., Bradbury, M. S., Wiesner, U. B., et al. (2022) · Chemistry of Materials · doi:10.1021/acs.chemmater.1c04447 · Cited by 16
Xu, M., Meng, X., Lu, Y., & Wang, F. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-897 · Cited by 16
Zhang, P., Tao, C., Shimura, T., Huang, A. C., Kong, N., Dai, Y., Yao, S., Xi, Y., Wang, X., Fang, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107272 · Cited by 17
Meattini, I., Andratschke, N. H., Kirby, A. M., Sviri, G. E., Offersen, B. V., Poortmans, P., & Kaidar‐Person, O. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02333-7 · Cited by 16
Major Strides in HER2 Blockade for Metastatic Breast Cancer
Sharma, P. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916310 · Cited by 16
Galuia, M., Fedorova, J., McHayleh, W. M., Mamounas, E., Ahmad, S., & Pavri, S. N. (2025) · Current Oncology · doi:10.3390/curroncol32030154 · Cited by 15
Choo, J. R.-E., Sargsyan, A., Khachatryan, V., Lonardi, S., Pietrantonio, F., Sundar, R., Klempner, S. J., & Janjigian, Y. Y. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01134-1 · Cited by 17
Johnson, M. L., Patel, M. R., Falchook, G. S., Koyama, T., Gutierrez, M., Awad, M. M., Piha-Paul, S. A., Friedman, C. F., Satoh, T., Okamoto, N., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00733-8 · Cited by 15
Laakmann, E., Witzel, I., Neunhöffer, T., Park‐Simon, T., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100495 · Cited by 15
Lander, E. M., Rappazzo, K. C., Huang, L., Hu, J., Chen, H., Shyr, Y., & Abramson, V. G. (2022) · The Oncologist · doi:10.1093/oncolo/oyac247 · Cited by 15
Tumor Targeting of 211At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis
Takashima, H., Ohnuki, K., Manabe, S., Koga, Y., Tsumura, R., Anzai, T., Wang, Y., Yin, X., Sato, N., Shigekawa, Y., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00869 · Cited by 15
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Suppan, C., & Balić, M. (2022) · Breast Care · doi:10.1159/000528756 · Cited by 16
Systemic treatments for breast cancer brain metastasis
Chen, Q., Xiong, J., Ma, Y., Wei, J., Liu, C., & Zhao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1086821 · Cited by 16
George, S., Heinrich, M. C., Somaiah, N., Oppelt, P., McLeod, R., Nishioka, S., Kundu, M. G., Qian, X., Kumar, P. K. M., Laadem, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0640 · Cited by 15
Li, H., Plichta, J. K., Li, K., Jin, Y., Thomas, S. M., Ma, F., Tang, L., Wei, Q., He, Y.-W., Chen, Q., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07171-z · Cited by 15
Lung toxicity induced by anti-HER2 antibody – drug conjugates for breast cancer
Chai, M., Li, L., Wu, H., Liu, Y., Yi, Z., & Yu, H. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104274 · Cited by 15
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
Liang, Y., Zhang, P., Li, F., Lai, H., Qi, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1332539 · Cited by 15
Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities
Selepe, C. T., Dhlamini, K. S., Tshweu, L. L., Moralo, M., Kwezi, L., Ray, S. S., & Ramalapa, B. (2024) · Nano Select · doi:10.1002/nano.202300191 · Cited by 15
HER2-Positive Metastatic Colorectal Cancer
Robinson, H. R., Messersmith, W. A., & Lentz, R. W. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01183-7 · Cited by 15
Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?
Zheng, H., Mahmood, S., Khalique, O. K., & Zhan, H. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00816 · Cited by 18
High, P. C., Guernsey-Biddle, C., Subramanian, S., Jacob, J., & Carmon, K. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070890 · Cited by 15
Ge, S., Wang, C., You, X., He, H., Zhang, B., Jia, T., Cai, X., Sang, S., Xu, T., & Deng, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00857 · Cited by 15
Sousa, M. F. E., Campainha, S., Marques, I. D., Dinis, R., Inácio, J. R., Mendes, J. J., Luís, R., Ferreira, A. M., Racha-Pacheco, R., Rolo, R., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01400-z · Cited by 15
Debbi, K., Benderra, M., Médioni, J., Durdux, C., To, N. H., Boukhobza, C., Grellier, N., Benmaziane, A., Monnier, L., Gligorov, J., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104421 · Cited by 15
Mortaja, M., Adams, S., McKay, R. R., Gutkind, J. S., & Advani, S. J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00885-x · Cited by 16
Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series
Stankowicz, M., Mauro, L. A., Harnden, K. K., & Pennisi, A. (2020) · Breast Care · doi:10.1159/000511049 · Cited by 15
Molinelli, C., Parisi, F., Razeti, M. G., Arecco, L., Cosso, M., Fregatti, P., Mastro, L. D., Poggio, F. B., & Lambertini, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1857243 · Cited by 15
Hepatic Metastasis from Breast Cancer
Liberchuk, A. N., & Deipolyi, A. R. (2020) · Seminars in Interventional Radiology · doi:10.1055/s-0040-1720949 · Cited by 15
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
Morales, S. M., Gasol, A., & Guzman, D. R. S. (2021) · Cancers · doi:10.3390/cancers13225771 · Cited by 15
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
Mills, M. N., King, W., Soyano, A. E., Piña, Y., Czerniecki, B. J., Forsyth, P. A., Soliman, H. H., Han, H. S., & Ahmed, K. A. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03977-x · Cited by 16
Zhang, L., Shen, D., Yu, L., Yan, Y., Wasan, H. S., Yu, J., Zhang, S., & Sun, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103758 · Cited by 15
Self-citationHo, E. C. H., Qiu, R., Miller, E., Bilotta, M. T., FitzGerald, D., & Antignani, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114047 · Cited by 15
Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes
Koehler, C., Sauter, P. F., Klasen, B., Waldmann, C. M., Pektor, S., Bausbacher, N., Lemke, E. A., & Miederer, M. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00634 · Cited by 15
Hu, Q., Wang, L., Yang, Y., & Lee, J. B. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.002 · Cited by 15
Wang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 14
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 17
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention
Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., Wang, S. M., & Chen, T. (2026) · MedComm · doi:10.1002/mco2.70560 · Cited by 15
Kawabata, H., Suzuki, H., Ohishi, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2022) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0048 · Cited by 14
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
Abelman, R. O., Medford, A. J., Spring, L. M., & Bardia, A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000634 · Cited by 14
Gonullu, B., Angeli, E., Pamoukdjian, F., & Bousquet, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043590 · Cited by 14
Hegedüs, L., Okumus, Ö., Mairinger, F. D., Plönes, T., Reuter, S., Schüler, M., Welt, A., Vega-Rubín-de-Celis, S., Theegarten, D., Bánkfalvi, Á., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.003 · Cited by 14
Guan, X., Ma, F., Li, Q., Chen, S., Fan, Y., Wang, J., Luo, Y., Zhang, P., Li, Q., & Xu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01322-w · Cited by 14
Self-citationSystemic Therapies for HER2-Positive Advanced Breast Cancer
Angelis, V., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers16010023 · Cited by 15
Navigating the Complexities of Brain Metastases Management
Amouzegar, A., Haig, S., Kahn, A. M., Tawbi, H. A., Jones, J., & Goldberg, S. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433694 · Cited by 15
Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158386 · Cited by 14
Zhang, R., Su, C., Jia, Y.-L., Xing, M., Jin, S., & Zong, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117363 · Cited by 16
Bartsch, R., Cameron, D., Ciruelos, E. M., Criscitiello, C., Curigliano, G., Duhoux, F. P., Foukakis, T., Gligorov, J., Harbeck, N., LeVasseur, N., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102853 · Cited by 15
Yang, P., Yao, X., Xue, T., Wang, Y., Gong, L., Yang, Y., & Jie, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101517 · Cited by 14
Ballhausen, A., Wheler, J. J., Karp, D. D., Piha-Paul, S. A., Fu, S., Pant, S., Tsimberidou, A. M., Hong, D. S., Subbiah, V., Holley, V. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2878 · Cited by 14
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer
Mishima, S., & Shitara, K. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1912007 · Cited by 15
Lv, H., Yan, M., & Jiang, Z. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211013326 · Cited by 14
Exploring the concepts and practices of advanced breast cancer treatment: a narrative review
Wang, X., Shao, X., Huang, J., Lei, L., Huang, Y., Zheng, Y., Cao, W., & Chen, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1458 · Cited by 14
Boyce-Fappiano, D. R., Bedrosian, I., Shen, Y., Lin, H. Y., Gjyshi, O., Yoder, A. K., Shaitelman, S. F., & Woodward, W. A. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00294-w · Cited by 14
Functional genomics for breast cancer drug target discovery
Yoshimaru, T., Nakamura, Y., & Katagiri, T. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00962-6 · Cited by 14
Lee, Y., Lee, M., Kim, H.-S., Kim, J., Ahn, J. S., Im, Y., & Park, Y. H. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1103 · Cited by 14
Self-citationHickish, T., Mehta, A. O., Liu, M.-C., Huang, C., Arora, R. S., Chang, Y., Yang, Y., Vladimirov, V. I., Jain, M. M., Tsang, J. W. H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06449-4 · Cited by 14
Moloney, C., & Shiely, F. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.03.011 · Cited by 16
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
Makhlin, I., & DeMichele, A. M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100668 · Cited by 14
Schlam, I. M., Nunes, R., & Lynce, F. C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s272197 · Cited by 14
Germline Testing in Prostate Cancer: When and Who to Test
Sokolova, A. O. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0645 · Cited by 14
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
